Skip to main content
DMRA
NASDAQ Life Sciences

Damora Q3 Loss Widens to $32.0M; $528.5M Cash Funds Runway Into 2H 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$22.94
Mkt Cap
$1.416B
52W Low
$4.95
52W High
$38.325
52W Position info
363% above low
Off High info
40% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

DMRA has more than doubled off its 52-week low of $4.95.

Summary

Damora's Q3 2026 net loss widened to $31.99M from $3.13M a year earlier on heavier R&D, while $528.5M in cash and securities funds operations into the second half of 2029. The filing also details the November 3 Paragon license for DMR-001 and DMR-002 and confirms the CLARITY-101 trial is underway.


Key Events · Earnings and Guidance · DMRA

  • Q3 Loss Widens on R&D Scale-Up

    Net loss was $31.99M for Q3 2026 versus $3.13M a year earlier, and the nine-month net loss reached $90.9M versus $9.1M. R&D expense rose to $25.5M from $1.4M, including $7.2M of Paragon-related costs.

  • Cash Funds Runway Into 2H 2029

    Cash, cash equivalents and marketable securities totaled $528.5M at September 30, 2026, which management says funds operations into the second half of 2029.

  • Paragon License Terms Disclosed

    The November 3, 2026 Paragon License Agreement for DMR-001 and DMR-002 carries up to $22.0M in milestones per licensed product, a $2.5M first-human-dosing milestone, and low-to-mid single-digit tiered royalties.

  • CLARITY-101 Trial Progresses

    The Phase 1/1b trial of DMR-001 started in Australia with FDA clearance for the U.S.; two proof-of-concept readouts are expected beginning mid-2027.


Analysis · DMRA · Life Sciences

The headline loss ballooned to $31.99M from $3.13M a year ago as R&D spending scaled up for the mutCALR antibody programs, but the balance sheet is the real story: $528.5M in cash and securities funds operations into the second half of 2029, so there is no near-term financing pressure. Hard terms also now attach to the November 3, 2026 Paragon license for DMR-001 and DMR-002 — up to $22.0M in milestones per product plus low-to-mid single-digit royalties. And the CLARITY-101 trial is running in Australia with FDA clearance for the U.S., with two proof-of-concept readouts expected beginning mid-2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DMRA was trading at $22.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $4.95 to $38.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DMRA - Latest Insights

DMRA
Nov 04, 2026, 4:06 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $23.22 info
Change: +$0.280 (+1%) info
Market Cap: $1.437B info
DMRA
Aug 10, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.54
Real-time Price: $23.22 info
Change: -$6.32 (-21%) info
Market Cap: $1.437B info
DMRA
Aug 05, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.02
Real-time Price: $23.22 info
Change: -$6.80 (-23%) info
Market Cap: $1.437B info
DMRA
May 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.06
Real-time Price: $23.22 info
Change: +$0.160 (+0.69%) info
Market Cap: $1.437B info
DMRA
May 04, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.98
Real-time Price: $23.22 info
Change: -$2.76 (-11%) info
Market Cap: $1.437B info